Depression Report

23 July 2018

This report compiles exclusive news and analysis based on interviews with key opinion leaders on market-moving events in the depression disorders space expected to occur in 2H.

A sampling of headlines:
• Acadia’s Phase II Nuplazid trial in depression sparks expert reservations on endpoint duration; safety profile poses no alarms
• SAGE’s brexanolone faces PPD uptake challenges due to potential reimbursement issues despite physician enthusiasm – experts
• SAGE’s brexanolone faces PPD uptake challenges due to potential reimbursement issues despite physician enthusiasm – experts